|
|
Profile
|
Delegates :
Kenji Sekikawa |
|
Incorporated :
March 31 , 2006 |
Paid in Capital :
75 Million yen |
Employees :
5 人 |
Address :
1-2, Owashi Tsukuba Ibaraki Japan 305-8634 IBARAKI
〒305-8634
|
TEL/FAX :
+81-29-838-6261 / +81-29-838-6028 |
URL：
http://www.preventec-inc.com/english.html |
Attachment :
 BioJapan_2014.pdf [ 9.7MiB ] |
Mission/Background :
PrevenTec, Inc. is a bio-venture company that aims to preventive medicine by biologics preparation and vaccine. The plant made pharmaceutical has become a reality in terms of safety and cost performance.We are developing cytokine and other biologic production by recombinant rice that can be produced without human pathogens, animal substance and endotoxin.
We focus on cytokine application in inflammatory diseases and auto-immune-diseases. We also are developing VLP vaccine. |
|
Technology & Business
|
Half-life of cytokines in the body are about 10 minutes and rapidly inactivated. Cytokine is working in the local microenvironment (cytokine milieu). Therefore it is necessary that there is no contamination in endotoxin of reference value, which may alter the cytokine milieu.
We have developed a stabilization method and topical administration method of cytokines. That can apply through the skin administration or mucosal administration (oral and intestinal tract).
We are developing the pipeline of IL-10 and PDGF-BB preparation for inflammatory, allergic diseases and autoimmune diseases.
|
|
Products & Service
|
Products & Service Name
|
Stage
|
Outline
|
Milestone
|
human IL-10
|
Others
|
Efficacy of IL-10 was found by oral administration of allergic model mouse.
|
clinical research
|
human PDGF-BB
|
Others
|
Activity evaluation in vitro
|
clinical research
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Highlights
|
Clinical trials of IL-10 and PDGF external preparation will be suggested to the following diseases: 1)psoriasis vulgaris, 2)atopic dermatitis, 3)allergy sublingual adjuvant, 4)stomatitis caused by cancer chemotherapy, 5)alopecia areata, 6)wound.
Currently we are conducting clinical research at Sapporo Medical University dermatology.
In addition, we are developing the dengue virus VLP vaccine collaborate with the University of Tsukuba.
|
|
Hot news
|
As a first step of the skin topical preparationt, We developed a beauty liquid, "Jeune Sante" which contain hIL-10 (human peptide 8 : INCI).
|
|
Alliance strategy
|
We are looking for an alliance company. to develop an anti-inflammation and an adjuvant for allergic and autoimmune diseases and anti-inflammation for wound healing and ischemia reperfusion injury.
|
|
|